Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Lima | Healthcare | Pharmaceuticals | PEN 3.02T | 110.4x | 8.3 | PEN 3,458.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Lima | Healthcare | Pharmaceuticals | PEN 1.43T | 10.2x | 0.11 | PEN 615.58 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Lima | Healthcare | Pharmaceuticals | PEN 1.03T | 20x | 0.06 | PEN 423.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Lima | Healthcare | Pharmaceuticals | PEN 616.48B | -63.7x | 0.56 | PEN 106.51 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Lima | Healthcare | Pharmaceuticals | PEN 405.28B | -16.7x | 0.09 | PEN 201.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Lima | Healthcare | Pharmaceuticals | PEN 392.33B | 100.2x | -1.24 | PEN 308.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |